A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (NCT04246086)

🧪 Interventions in This Study

• Mosunetuzumab (IV) (DRUG)
• Tocilizumab (DRUG)
• Lenalidomide (DRUG)
• Mosunetuzumab (SC) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• City of Hope National Medical Center — Duarte, California
• University of Miami Miller School of Medicine — Miami, Florida
• Norton Cancer Institute - St. Matthews — Louisville, Kentucky
• Mary Bird Perkins Cancer Ctr — Baton Rouge, Louisiana
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
• Duke University Medical Center — Durham, North Carolina
• Fairview Hospital — Cleveland, Ohio
• Cleveland Clinic — Cleveland, Ohio
• Hillcrest Hospital — Mayfield Heights, Ohio
• Rhode Island Hematology/Oncology Program — Woonsocket, Rhode Island
• Tennessee Oncology;Chattanooga Oncology & Hematology Associates — Chattanooga, Tennessee
• Tennessee Oncology PLLC - Franklin — Franklin, Tennessee
• Swedish Medical Center — Seattle, Washington
• The First Hospital of Jilin University — Changchun,
• West China Hospital, Sichuan University — Chengdu,
• Fudan University Shanghai Cancer Center — Shanghai,
• Tianjin Medical University Cancer Institute & Hospital — Tianjing,
• The First Affiliated Hospital of Xiamen University — Xiamen,
• Centre Hospitalier Lyon Sud — Pierre-Bénite,
• CHU Rennes - Hopital Pontchaillou — Rennes,
• Hospital Universitario Fundacion Jimenez Diaz. — Madrid,
• Hospital Universitario Virgen de la Victoria — Málaga,
• University College London Hospitals NHS Foundation Trust - University College Hospital — London,
• The Christie NHS Foundation Trust — Manchester,
• Freeman Hospital — Newcastle upon Tyne,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Follicular Lymphoma

• A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
• Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
• Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
• Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Concord, California

Explore by condition: All Follicular Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.